Cost comparison of post-remission strategies in younger and older AML patients in France

被引：0
|
作者：
Michael Mounie
Pierre-Yves Dumas
Sandra Liva-Yonnet
Didier Fabre
Thibault Leguay
Jean Galtier
Emilie Berard
Ramaroson Hanta
Véronique Gilleron
Sarah Bertoli
Arnaud Pigneux
Christian Récher
Nadège Costa
机构：
[1] Centre Hospitalier Universitaire (CHU),Unité d’Evaluation Médico
[2] Institut National de la Santé et de la Recherche Médicale,Economique
[3] CHU Bordeaux,Département d’Information Médicale
[4] Service d’Hématologie Clinique et de Thérapie Cellulaire,Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse
[5] Université de Bordeaux,Cancer Research Center of Toulouse, Unité Mixte de Recherche (UMR) 1037 INSERM
[6] Institut National de la Santé et de la Recherche Médicale,undefined
[7] Centre Hospitalier Universitaire (CHU),undefined
[8] Département d’Information Médicale,undefined
[9] Centre Hospitalier Universitaire (CHU),undefined
[10] Institut Universitaire du Cancer de Toulouse Oncopole,undefined
[11] Université Toulouse III Paul Sabatier,undefined
[12] ERL5294 Centre National de la Recherche Scientifique,undefined
来源：
Blood Cancer Journal | / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] The role of autologous haematopoetic stem cell transplantation in post-remission therapy of AML
    Durakovic, N.
    Batinic, J.
    Sertic, D.
    Bojanic, I.
    Batinic, D.
    Golubic-Cepulic, B.
    Nemet, D.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 : S392 - S393
  • [22] Impact of post-remission therapy on survival of older patients with AML treated with intensive chemotherapy: Results of the multicenter ALFA-9803 trial.
    Turlure, Pascal
    Gardin, Claude
    Malfuson, Jean-Valere
    Thomas, Xavier
    Terre, Christine
    Contentin, Nathalie
    Raffoux, Emmanuel
    de Botton, Stephane
    Pautas, Cecile
    Reman, Oumedaly
    Bourhis, Jean-Henri
    Dhedin, Nathalie
    Janvier, Maud
    Fenaux, Pierre
    Castaigne, Sylvie
    Michallet, Mauricette
    Preudhomme, Claude
    de Revel, Thierry
    Bordessoule, Dominique
    Dombret, Herve
    [J]. BLOOD, 2006, 108 (11) : 128A - 129A
  • [23] Mast Cell Sarcoma in a Post-Remission AML Patient: Case Report and Review of Literature
    Elbogdady, Mohamed
    Taalab, Mona
    Zaki, Marwa A. F.
    Atef, Basma
    Talaat, Ahmed
    Emesh, Atef
    Elazab, Ahmed
    Dheim, Safaa
    Elshamy, Alaa
    Elbogdady, Aya
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S189 - S190
  • [24] Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
    Stone, Richard M.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2011, 24 (04) : 509 - 514
  • [25] PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)
    Walter, B.
    Medeiros, B.
    Nielsen-Stoeck, M.
    Harrington, E.
    Powell, B.
    Schiffer, C.
    Appelbaum, F.
    Estey, E.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 29 - 30
  • [26] Gemtuzumab Ozogamicin in Combination with Vorinostat and Azacitidine As Induction and Post-Remission Therapy in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase 1 Study
    Walter, Roland B.
    Medeiros, Bruno C.
    Gardner, Kelda M.
    Estey, Elihu H.
    [J]. BLOOD, 2011, 118 (21) : 670 - 670
  • [27] Fluoroquinolone Prophylaxis in Acute Myeloid Leukemia (AML) Patients Undergoing Post-Remission Chemotherapy Reduces Hospital Admission Rates
    Kusick, Karissa
    Earl, Marc
    Gallagher, Erika M.
    Yeh, Jun-Yen
    Advani, Anjali S.
    Kalaycio, Matt
    Copelan, Edward A.
    Sekeres, Mikkael A.
    [J]. BLOOD, 2011, 118 (21) : 1103 - 1103
  • [28] The intention to treat analysis of the different post-remission therapy modalities in AML patients with the Intermediate Risk Group based on cytogenetics
    Mun, Y. C.
    Lee, S. M.
    Park, S. H.
    Cho, E. K.
    Lee, J. H.
    Jo, D. Y.
    Kim, I. H.
    Yoon, S. S.
    Park, S. Y.
    Bang, S. M.
    Min, Y. J.
    Seo, J. J.
    Lee, M. H.
    Kim, C. S.
    Joo, Y. D.
    Chung, S. Y.
    Oh, D. Y.
    Jang, D. Y.
    Lee, K. H.
    Hyun, M. S.
    Song, H. S.
    Kim, H. S.
    Kwon, K. Y.
    Kwon, H. C.
    Kim, H. J.
    Park, Y. H.
    Ahn, M. J.
    Ahn, J. S.
    Park, K. T.
    Bae, S. H.
    Ryoo, H. M.
    Yoon, H. J.
    Kim, B. S.
    Ghim, T.
    Seong, C. M.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 : S60 - S60
  • [29] Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study
    Baron, Frederic
    Efficace, Fabio
    Cannella, Laura
    Mandelli, Franco
    Willemze, Roelof
    Muus, Petra
    Marie, Jean-Pierre
    Ferrero, Dario
    Dictus, Marlies
    Fazi, Paola
    La Sala, Edoardo
    Bourhis, Jean-Henri
    Fabbiano, Francesco
    Bosi, Alberto
    Sborgia, Marco
    Martinelli, Giovanni
    Bron, Dominique
    Petti, Maria C.
    Halkes, Constantijn J. M.
    van der Velden, Walter J. F. M.
    Boccadoro, Mario
    Amadori, Sergio
    Zittoun, Robert A.
    Suciu, Stefan
    [J]. BLOOD, 2016, 128 (22)
  • [30] Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)
    Tanaka, Tomoyuki
    Morita, Kiyomi
    Wang, Feng
    Little, Latasha
    Gumbs, Curtis
    Matthews, Jairo
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Ravandi, Farhad
    Konopleva, Marina Y.
    Kantarjian, Hagop M.
    Champlin, Richard E.
    Garcia-Manero, Guillermo
    Futreal, P. Andrew
    Takahashi, Koichi
    [J]. BLOOD, 2019, 134
12345